istock-104821184
Chris Ryan / iStockphoto.com
28 August 2018Americas

US judge invalidates Pernix patents in Alvogen clash

Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Americas
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.

More on this story

Big Pharma
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Americas
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.

More on this story

Big Pharma
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Americas
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.